Hormone-Resistant Breast Carcinoma — Trials

Hormone-Resistant Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 100%
Top sponsor: A&G Pharmaceutical Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05627960	First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies	recruiting	Phase 1	77	A&G Pharmaceutical Inc.INDUSTRY	1	Nov 28, 2022	clinicaltrials

Data updated 23 days agoSource updated Nov 28, 2022source: clinicaltrials